Guided Therapeutics (GTHP) Change in Receivables (2016 - 2025)

Guided Therapeutics' Change in Receivables history spans 15 years, with the latest figure at $8000.0 for Q2 2025.

  • On a quarterly basis, Change in Receivables rose 366.67% to $8000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $7000.0, a 216.67% increase, with the full-year FY2025 number at $7000.0, up 216.67% from a year prior.
  • Change in Receivables hit $8000.0 in Q2 2025 for Guided Therapeutics, up from -$1000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for GTHP hit a ceiling of $22000.0 in Q4 2021 and a floor of -$32000.0 in Q3 2022.
  • Historically, Change in Receivables has averaged $769.23 across 5 years, with a median of -$1000.0 in 2023.
  • The widest YoY moves for Change in Receivables: up 600.0% in 2022, down 1700.0% in 2022.
  • Tracing GTHP's Change in Receivables over 5 years: stood at $22000.0 in 2021, then crashed by 245.45% to -$32000.0 in 2022, then surged by 112.5% to $4000.0 in 2023, then plummeted by 150.0% to -$2000.0 in 2024, then surged by 500.0% to $8000.0 in 2025.
  • Business Quant data shows Change in Receivables for GTHP at $8000.0 in Q2 2025, -$1000.0 in Q1 2025, and -$2000.0 in Q4 2024.